18:27 , Oct 19, 2018 |  BC Week In Review  |  Company News

Roche culls pipeline, cuts include in-licensed, acquired programs

Roche (SIX:ROG; OTCQX:RHHBY) announced in its 3Q18 earnings it discontinued development of five new molecular entities, including Phase II rheumatoid arthritis candidate RG6125 (SDP051), plus two programs in development for follow-on indications. The pharma lost...
12:26 , Oct 19, 2018 |  BC Extra  |  Financial News

Ahead of Phase II, TP raises $80M mezzanine round

Oncology company TP Therapeutics Inc. (San Diego, Calif.) raised $80 million in a mezzanine round and promoted Athena Countouriotis to CEO from CMO as the company readies to begin a potentially registrational Phase II study...
21:29 , Oct 17, 2018 |  BC Extra  |  Company News

Roche culls pipeline, cuts include in-licensed, acquired programs

Roche (SIX:ROG; OTCQX:RHHBY) announced in its 3Q18 earnings it discontinued development of five new molecular entities, including Phase II rheumatoid arthritis candidate RG6125 (SDP051), plus two programs in development for follow-on indications. The pharma lost...
19:15 , Jul 20, 2018 |  BC Week In Review  |  Financial News

Provention raises $64M IPO

Autoimmune and infectious disease company Provention Bio Inc. (NASDAQ:PRVB) raised $63.9 million on July 19 through the sale of 16 million shares at $4 in an IPO underwritten by MDB Capital Group and Dougherty &...
00:15 , Jul 20, 2018 |  BC Extra  |  Financial News

Provention raises $64M IPO

Autoimmune and infectious disease company Provention Bio Inc. (NASDAQ:PRVB) raised $63.9 million on Thursday through the sale of 16 million shares at $4 in an IPO underwritten by MDB Capital Group and Dougherty & Co....
15:31 , Jun 8, 2018 |  BC Week In Review  |  Clinical News

Daiichi planning NDA for pexidartinib on Phase III TGCT data

Daiichi Sankyo Co. Ltd. (Tokyo:4568) reported data from 120 patients with symptomatic advanced tenosynovial giant cell tumors (TGCT) in the Phase III ENLIVEN trial showing that oral pexidartinib (PLX3397) led to an overall response rate...
22:43 , Jun 5, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Neurology Mouse studies suggest CSF1R inhibitors could help treat age-related neurodegeneration. In a mouse model of age-related neurodegeneration, a tool compound CSF1R inhibitor decreased markers of age-related neuropathy including the numbers of thinly myelinated...
18:08 , May 11, 2018 |  BC Week In Review  |  Financial News

Provention plans IPO, reveals MacroGenics deal

Autoimmune and infectious disease company Provention Bio Inc. (Lebanon, N.J.) proposed on May 9 to raise up to $50 million in an IPO underwritten by MDB Capital Group. The company's pipeline includes several candidates in-licensed...
20:14 , May 10, 2018 |  BC Extra  |  Financial News

Provention plans IPO, reveals MacroGenics deal

Autoimmune and infectious disease company Provention Bio Inc. (Lebanon, N.J.) proposed to raise up to $50 million in an IPO underwritten by MDB Capital Group. The company's pipeline includes several candidates in-licensed from other companies...
21:28 , Feb 9, 2018 |  BioCentury  |  Emerging Company Profile

Fast boat to China

Abbisko Therapeutics aims to be first-to-market for common cancer indications in China with small molecules against clinically validated targets that are more potent than competing agents in development outside the country. Abbisko is focusing first...